Company Profile
Patrys develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10
PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and chemotherapy drugs. The company was incorporated in 2006 and is based in Nedlands, Australia.